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ABSTRACT
Background: Oxidative stress and inflammation of the arterial wall are 
now recognized as important factors in the progression of atherosclerosis. C-reactive 
protein (CRP) has been defined as a sensitive but not specific marker of inflamma-
tion. Statin therapy has been reported to decrease plasma high-sensitivity CRP (hs-CRP) 
concentration in hypercholesterolemic patients. 
Objective: The aim of this study was to examine the effect of rosuvastatin on 
concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma 
hs-CRP in hypercholesterolemic patients with and without type 2 diabetes mellitus.
Methods: Patients with hypercholesterolemia with and without type 2 diabetes 
mellitus were enrolled in this pilot study after written informed consent was given. 
At baseline and after 12 weeks of open-label treatment with rosuvastatin 2.5 mg/d, 
concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma 
hs-CRP were measured. Urine 8-iso-prostaglandin F2α (8-iso-PGF2α) and 8-hydroxy-2'- 
deoxyguanosine (8-OHdG) concentrations were also measured to assess whole-body oxi-
dative stress. Plasma free-radical generation was estimated using a total reactive oxygen 
species (TROS) assay system. Adverse effects were assessed at each study visit (4-week 
intervals) through patient interviews and laboratory testing. 
Results: Thirty-five patients were enrolled with 1 dropping out prior to 
study completion; therefore, 34 patients (19 women, 15 men; mean [SE] age, 
55.4 [13.6] years; range, 30–78 years) completed the study. Compared with baseline, 
significant decreases were found in serum concentrations of total cholesterol (TC) 
(252.3 [39.3] vs 187.8 [30.1] mg/dL; P < 0.001; Δ = 24.5%), LDL-C (162.0 [44.3] vs 
98.5 [31.9] mg/dL; P < 0.001; Δ = 38.7%), and triglycerides (TG) (157.2 [93.6] vs 
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124.4 [69.9] mg/dL; P < 0.05; Δ = 11.7%) after 12 weeks of treatment with rosu-
vastatin. Serum HDL-C concentration did not change significantly from baseline 
(59.7 [20.5] vs 63.7 [19.3] mg/dL; Δ = 9.4%). The plasma LDL-C/HDL-C ratio de-
creased significantly after rosuvastatin treatment (3.03 [1.33] vs 1.72 [0.83]; P < 
0.001; Δ = 43.2%). Compared with baseline, significant decreases were observed 
in urine concentrations of the oxidative stress markers after 12 weeks of rosuvastatin 
treatment: 8-iso-PGF2α (342.8 [154.3] vs 300.6 [101.2] pg/mg; P < 0.05) and 
8-OHdG (11.1 [4.53] vs 8.1 [2.7] ng/mg; P < 0.01). TROS decreased significantly 
(182.3 [29.0] vs 157.6 [17.3] U; P < 0.001), and plasma hs-CRP concentration also 
decreased significantly (0.107 [0.100] vs 0.054 [0.033] mg/dL; P < 0.05). When the 
patients’ results were assessed according to the presence or absence of type 2 diabetes 
mellitus, urine 8-iso-PGF2α concentration was significantly decreased from baseline 
only in the nondiabetic group. No adverse events were reported or observed during 
the course of the study.
Conclusion: Rosuvastatin treatment was associated with significant reduc-
tions in plasma concentrations of TC, LDL-C, and TG, urine and plasma oxidative 
stress markers, and plasma hs-CRP in these hypercholesterolemic patients. (Curr Ther 
Res Clin Exp. 2009;70:439–448) © 2009 Excerpta Medica Inc.
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INTRODUCTION
Increased plasma LDL-C concentration is an important risk factor for coronary artery 
disease (CAD).1 Diabetes mellitus is an independent risk factor for CAD.2 Therefore, 
diabetes mellitus in patients with elevated plasma LDL-C concentration may further 
increase the risk of CAD.
Large-scale clinical trials indicated that intervention with hydroxy-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors (statins) successfully reduced cardiovas-
cular events in patients with type 2 diabetes mellitus and increased plasma LDL-C 
concentration.3–5 The risk reduction rate with statin therapy may be greater than the 
decrease in plasma LDL-C concentration would suggest.6–8 This risk reduction mech-
anism, which is independent of the effect on cholesterol, is called the pleiotropic effect.9 
The pleiotropic effect may include antiinflammatory8 and antioxidative actions,10 
thereby contributing to arterial wall protection.
The HMC-CoA reductase inhibitor rosuvastatin 2.5 mg/d was reported to have a 
beneficial effect on the plasma lipid profile: concentrations of LDL-C, total cholesterol 
(TC), and triglycerides (TG) were reported to decrease by 39%, 25%, and 12% from 
baseline, respectively, and HDL-C was reported to increase by 9%.11 
Oxidative stress induces the activation of endothelial and smooth muscle cells in 
the vascular wall as well as the oxidation of LDL particles. The oxidized LDL particles 
are then taken up by macrophages, leading to the formation of atherosclerotic 
plaque.12,13 Therefore, plasma oxidized LDL concentration14 and plasma and urine 
oxidative stress marker concentrations15–17 may be surrogate markers for the progres-
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sion of atherosclerosis. Oxidative stress is increased in patients with hyperglycemia 
and the susceptibility of LDL to oxidation is increased in poorly controlled type 1 dia-
betes mellitus.18
Atherosclerosis is now recognized as an inflammatory disease in which the immune 
mechanism, triggered by endothelial injury, interacts with metabolic risk factors, re-
sulting in initiation, propagation, and activation of lesions in the arterial wall.19 It is 
now recommended that inflammatory-response proteins be considered predictors of 
cardiovascular events.20 C-reactive protein (CRP) has been defined as a sensitive but 
nonspecific marker of inflammation. Therefore, a high-sensitivity CRP (hs-CRP) 
assay is considered useful in predicting coronary risk.21 Furthermore, statin therapy 
has been reported to decrease plasma hs-CRP concentration in hypercholesterolemic 
patients.22
Although antioxidative effects of statins have been reported,22 simultaneous moni-
toring of antioxidative effects of statins from plasma and urine samples has not been 
reported. Therefore, the primary and secondary outcome measures of this study were 
the effect of rosuvastatin on oxidative stress markers in both plasma and urine, and on 
plasma hs-CRP in hypercholesterolemic patients with and without type 2 diabetes 
mellitus.
PATIENTS AND METHODS
Outpatients with hypercholesterolemia who were being treated in the Division of 
Diabetes, Metabolism and Endocrinology, Ohmori Hospital Medical Center, Toho 
University (Tokyo, Japan) and who had been receiving dietary treatment for dyslipi-
demia and/or type 2 diabetes mellitus were screened for inclusion and enrolled in this 
study. Patients were excluded based on the results of routine serum biochemical analysis 
if they had hepatic, renal, or thyroid disease. The study began in April 2006.
All study protocols and procedures were approved by the ethics committee of 
Ohmori Hospital Medical Center, Toho University. The study objectives and intended 
measures were explained individually to the prospective study patients. Written in-
formed consent was obtained from all study participants. 
Rosuvastatin 2.5 mg/d was administered to all patients for 12 weeks. Before and 
after treatment with rosuvastatin, concentrations of plasma lipids, urine and plasma 
oxidative stress markers, and plasma hs-CRP were measured. All hypoglycemic drugs 
that diabetic patients were taking when they entered the study were continued with-
out any changes in dose or mode of administration. Dietary and exercise treatments 
were also continued, and the patients were advised not to change their lifestyle.
Blood samples were collected in tubes containing EDTA (1.5 g/L) and centrifuged 
at 1000g for 20 minutes at 4°C to obtain plasma. Blood glucose and glycosylated 
hemoglobin (HbA1c) were measured by glucose oxidase method and HPLC, re-
spectively. Plasma lipid concentrations were measured using an autoanalyzer 
(LABOSPCT008, Hitachi Co., Ltd., Tokyo, Japan). Urine concentrations of 
8-iso-prostaglandin F2α (8-iso-PGF2B)
 23 and 8-hydroxy-2'-deoxyguanosine (8-OHdG)17 
were also measured using an enzyme-linked immunosorbent assay to monitor whole-
body oxidative stress. Plasma free-radical generation was estimated using a total reac-
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tive oxygen species (TROS) assay system15 at an external laboratory (SRL Co., Ltd, 
Hachioji, Japan). Plasma hs-CRP concentration was measured using the methods of 
Ledue et al.24 Compliance with the rosuvastatin regimen was monitored by interview 
at each study visit (4-week intervals).
To monitor the adverse effects possibly associated with rosuvastatin, clinical symp-
toms (eg, headache, nausea, stomachache, muscle pain) were assessed by questionnaire 
and observation, and blood samples were drawn for routine biochemical analyses 
(aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, uric 
acid, creatinine, and lactate dehydrogenase) at each visit.
Statistical Analysis
Statistical analysis was performed using SPSS version 10.0J (SPSS Inc., Chicago, 
Illinois). All values are expressed as mean (SE). Paired t tests were used to compare the 
data before and after rosuvastatin treatment. P < 0.05 was considered statistically 
significant. A sample-size calculation was not performed.
RESULTS
Thirty-five outpatients with hypercholesterolemia were enrolled in the study; 1 pa-
tient was lost to follow up prior to completion, but the patient’s data were used in 
the statistical anlysis (Table I). Therefore, 34 patients (19 women, 15 men; mean 
[SE] age, 55.4 [13.6] years; range, 30–78 years) completed the study. Nineteen of the 
study patients were diabetic and 13 were hypertensive.
Compared with baseline, significant decreases were found in serum concentrations 
of TC (252.3 [39.3] vs 187.8 [30.1] mg/dL, respectively; P < 0.001; Δ = 24.5%), LDL-C 
(162.0 [44.3] vs 98.5 [31.9] mg/dL; P < 0.001; Δ = 38.7%), and TG (157.2 [93.6] vs 
124.4 [69.9] mg/dL; P < 0.05; Δ = 11.7%) after 12 weeks of treatment with rosuva-
statin. Serum HDL-C concentration did not change significantly from baseline 
(59.7 [20.5] vs 63.7 [19.3] mg/dL; Δ = 9.4%). After 12 weeks of rosuvastatin therapy, 
the plasma LDL-C/HDL-C ratio decreased significantly (3.03 [1.33] vs 1.72 [0.83]; 
P < 0.001; Δ = 43.2%).
After treatment, no significant differences were observed in fasting blood glucose 
or HbA1c concentration compared with baseline in the diabetic patients (Table II).
Compared with baseline, significant decreases were observed in the urine oxidative 
stress markers after 12 weeks of rosuvastatin treatment: 8-iso-PGF2α (342.8 [154.3] 
vs 300.6 [101.2] pg/mg, respectively; P < 0.05) and 8-OHdG (11.1 [4.53] vs 8.1 
[2.7] ng/mg; P < 0.01). TROS, an index of free radical generation in blood, decreased sig- 
nificantly (182.3 [29.0] vs 157.6 [17.3] U; P < 0.001). Plasma hs-CRP concentration 
also decreased significantly from baseline (0.107 [0.100] vs 0.054 [0.033] mg/dL; 
P < 0.05).
Compared with baseline, when the patients were divided into 2 groups according to the 
presence or absence of type 2 diabetes mellitus, a significant decrease was found after 
12 weeks of rosuvastatin treatment in the urine 8-iso-PGF2α concentration in the nondia-
betic patients (350.6 [43.4] vs 301.7 [36.1] pg/mg, respectively; P < 0.05), while no 
significant change was found in diabetic patients (362.0 [49.9] vs 366.2 [35.6] pg/mg).
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Table I.  Baseline demographic and clinical characteristics of the 
study patients (N = 34).
Characteristic Value
Age, y 
  Mean (SE) 55.4 (13.6)
  Range 30–78
Sex, no.
  Women 19
  Men 15
Plasma TC, mean (SE), mg/dL 252.3 (39.3)
Plasma LDL-C, mean (SE), mg/dL 162.0 (44.3)
Plasma TG, mean (SE), mg/dL 157.2 (93.6)
Plasma HDL-C, mean (SE), mg/dL 59.7 (20.5)
HbA1c, mean (SE), %* 7.8 (1.7)
BMI, mean (SE), kg/m2 24.6 (3.3)
SBP, mean (SE), mm Hg 126.4 (3.0)
DBP, mean (SE), mm Hg 75.0 (3.2)
Concomitant drugs, no. of patients
  ARBs 12
TC = total cholesterol; TG = triglycerides; HbA1c = glycosylated hemoglobin; 
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic 
blood pressure; ARB = angiotensin II receptor blocker.
* Measured in 21 patients (19 with type 2 diabetes and 2 with impaired 
glucose tolerance).
Table II.  Laboratory findings at baseline and after 3 months of rosuvastatin treatment. 
Values are mean (SE).*
 No. of  After 12 Weeks of 
Laboratory Finding Patients Baseline Rosuvastatin Treatment
Blood glucose, mg/dL 34 149.4 (57.3) 151.8 (51.8)
HbA1c, % 21 7.8 (1.7) 7.7 (1.6)
Serum CK, IU/L 34 80.6 (40.2) 84.9 (53.5)
Serum ALT, IU/L 34 21.4 (11.3) 23.4 (11.4)
Serum Cr, mg/dL 34 0.82 (0.55) 0.82 (0.53)
HbA1c = glycosylated hemoglobin; CK = creatine kinase; ALT = alanine aminotransferase; Cr = 
creatinine.
*No significant differences were found between baseline and posttreatment.
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No simple correlations were found between changes in serum LDL-C concentration 
and TROS or plasma hs-CRP concentration before and after rosuvastatin treatment.
During the study, rosuvastatin was well tolerated. No adverse events, including the 
occurrence of clinical symptoms or changes in the biochemical parameters studied, 
were detected or reported (Table II).
DISCUSSION
In the present study, rosuvastatin 2.5 mg/d was associated with a decrease in plasma 
LDL-C concentration was comparable to that found in a previous study in which 
rosuvastatin 5 mg/d was administered to hypercholesterolemic Japanese patients.11 
While epidemiologic studies have reported that a high plasma LDL-C concentration 
is the most important risk factor for ischemic heart diseases,1,25 the reduction in the 
risk of ischemic heart diseases is not always proportional to the reduction in plasma 
LDL-C concentration in hypercholesterolemic patients.6–8 Therefore, atherogenic con-
ditions other than a high plasma LDL-C concentration became a focus of research on 
atherosclerosis prevention. Oxidative stress markers are now recognized as risk factors 
for CAD.
The urine oxidative stress marker 8-iso-PGF2α is produced nonenzymatically via 
the direct oxidation of the end product of arachidonic acid cascade. 8-Iso-PGF2α is 
released from circulating lipoproteins and phospholipids on the cell surface by free 
radicals.26 Urine 8-iso-PGF2α concentration is being evaluated as a marker for oxida-
tive stress because of evidence of a correlation between its circulating concentration 
and the degree of cellular damage and lipoperoxidation.27 In addition, an increase in 
this marker has previously been reported in patients with hypercholesterolemia28 and 
diabetes16 and in individuals who smoke.29 Urine 8-iso-PGF2α concentration has also 
been associated with elevated fasting blood glucose and HbA1c concentrations in pa-
tients with type 2 diabetes mellitus and in individuals who smoke.30 In addition, 
8-iso-PGF2α was found in atherosclerotic lesions in humans,
31 suggesting that this 
might be a clinical predictor of atherosclerosis. An open-label trial found that <20 mg 
per day of fluvastatin administration for 6 months suppressed the urine 8-iso-PGF2α 
concentration in 15 hypercholesterolemic patients.32
The urine oxidative stress marker 8-OHdG is produced when active oxygen reacts 
with guanine bases in DNA, thereby serving as a biological marker of oxidative dam-
age to DNA. Active oxygen species (singlet oxygen, hydroxyl radical, hydrogen per-
oxide, and superoxide) are involved in 8-OHdG production. When DNA is subjected 
to oxidative damage, it undergoes repeated repairs, resulting in the released DNA 
being excreted as an end product in urine. This urine marker was found to be a useful 
indicator of therapeutic efficacy in patients with lung cancer who received irradiation 
therapy or chemotherapy.17 It has also been reported to increase under mental stress33 
and to decrease after angiotensin II receptor blocker (ARB) administration.34 In the 
patients with type 2 diabetes mellitus in our study, rosuvastatin was associated with 
a significantly suppressed urine 8-OHdG concentration, while no significant changes 
were observed in simultaneously measured urine 8-iso-PGF2α concentration. How-
ever, when the entire study population was considered, both urine 8-iso-PGF2α and 
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8-OHdG concentrations decreased significantly after rosuvastatin treatment. Because 
oxidative stress was found to be increased in hyperglycemia,18 this might have inter-
fered with the antioxidative action of rosuvastatin in the patients with type 2 diabetes 
mellitus, as estimated by monitoring urine 8-iso-PGF2α concentration. Alternatively, 
the difference in antioxidative stress with rosuvastatin treatment between diabetic and 
nondiabetic patients might be attributable to differences in the effects of rosuvastatin 
that depend on the type of active-oxygen species measured. Therefore, these 2 oxida-
tive stress markers may have different clinical implications. However, no studies have 
focused on the differences in the oxidative processes between the 2 markers, and it is 
difficult to clarify differences in the mechanisms of oxidation in clinical settings.
In this study, we used the TROS assay system, in which free radicals generated 
from peroxides by the Fenton reaction using a metal catalyzer are reacted with alkyl 
amines, and the reacted alkyl amines are detected using the colorimetric method at a 
wavelength of 505 nm.15 Hayashi et al35 reported that the serum active oxygen con-
centration in diabetic patients was significantly higher than that in nondiabetic sub-
jects. In the present study, although there was no difference in serum active oxygen 
concentration between diabetic and nondiabetic patients, it was significantly decreased 
after rosuvastatin treatment.
We used 3 oxidative stress markers to examine the antioxidative effect of rosuva-
statin and found that all the markers were suppressed following rosuvastatin treat-
ment. Further study is necessary to determine if the reduction of these markers with 
rosuvastatin treatment translates into a clinical benefit. Although the precise mecha-
nisms for the antioxidative power of rosuvastatin are not known, these findings sug-
gest its antioxidative potential.
Chronic inflammation is involved in the development of atherosclerosis.19,20 The 
inflammatory marker hs-CRP was found to correlate with the development of CAD. 
Patients with high plasma hs-CRP concentration were found to be at higher risk for 
acute myocardial infarction compared with those with a low hs-CRP concentra-
tion.20 Although the effects of statins on plasma hs-CRP concentration have been 
reported,22 ours was the first study to find that rosuvastatin was associated with 
a significant reduction of the marker, even in a limited population of patients with 
concomitant type 2 diabetes mellitus who may have had vascular damage due to 
hyperglycemia.
No simple correlations were found between changes in concentrations of serum 
LDL-C and the 2 urine oxidative stress markers, TROS or plasma hs-CRP, before and 
after rosuvastatin treatment. This suggests that the changes in the 2 urine oxidative 
stress markers, free radical production in blood, and plasma hs-CRP concentration 
were induced not by lowering the plasma LDL-C concentration but by the pleiotropic 
effects of rosuvastatin. In a previous study in hypercholesterolemic patients,32 we re-
ported that treatment with fluvastatin reduced oxidative stress, as indicated by a 
decrease in urine 8-iso-PGF2α concentration and an increase in the size of the LDL 
particles. Although such pleiotropic effects have been reported with other statins,9 
further studies are needed to determine whether there is any difference in the level 
of these effects among statins with different properties.
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This was a small, open-label, uncontrolled, prospective study, and some of the 
enrolled patients were already receiving ARBs, which are reported to be associated 
with antioxidative stress.36 Additionally, the observation period was only 12 weeks, 
which was not sufficient time to determine the long-term prognosis of these patients. 
Therefore, further study is necessary to confirm the antioxidative and antiinflammatory 
effects of rosuvastatin.
CONCLUSION
Rosuvastatin treatment was associated with significant reductions in concentrations 
of plasma LDL-C, TC, and TG, in plasma and urine oxidative stress markers, and in 
the inflammatory marker of hs-CRP in these patients with hypercholesterolemia.
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